# US 2015/0177241 A1 · Biomarkers of immune response in mucosal lesions and their use with therapeutic vaccination

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177241 A1
- Document ID: US20150177241A1
- Status: Published application
- Kind: A1
- Application number: 14/576,551
- Filed: 2014-12-19
- Published: 2015-06-25
- Earliest claimed: 2013-12-20
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Cornelia Trimble
- Web page: https://patentgrep.com/patent/US20150177241A1

## CPC

- G01N 33/56972: {White blood cells}
- A61K 39/12: Viral antigens
- G01N 33/5755: of the uterine cervix, uterine corpus or endometrium
- A61K 2039/53: {DNA (RNA) vaccination}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- A61K 2039/55: {characterised by the host/recipient, e.g. newborn with maternal antibodies}
- A61K 2039/572: {cytotoxic response}
- A61K 2039/585: {wherein the target is cancer}
- C12N 2710/20034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2710/24143: viral genome or elements thereof as genetic vector
- G01N 2333/70517: CD8
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides evidence of post-vaccination immunologic changes in target HPV induced cervical intraepithelial neoplasias that suggest the induction of clinically relevant tissue-localized immune responses, despite modest detectable responses in circulating T lymphocytes. The inventive methods allow for identification of immunological responses to HPV immunotherapies, and means for monitoring responses during clinical trials and treatment regimens.

## Claims

### Claim 1

A method for determining the effectiveness of an HPV vaccine regimen on a subject having a cervical intraepithelial neoplasia (CIN) comprising: a) obtaining at least one first tissue sample from the CIN of the subject; b) administering to the subject a first vaccine construct comprising HPV16 E7 antigen one or more times; c) administering to the subject a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18; d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c); e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples; and f) determining that the HPV vaccine regimen is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein at step d), the at least one or more samples are obtained at 4 weeks to about 8 weeks after step c).

### Claim 3 (depends on 1)

The method of claim 1, wherein at step f), when the amount of CD8+ T cell infiltrates in the second tissue sample is the same or decreased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample, then the HOV vaccine regimen is determined to be ineffective.

### Claim 4 (depends on 1)

The method of claim 1, further comprising: step e1) measuring the quantity of Treg cells in the intraepithelial tissue of the first and second CIN samples; and f1) determining that the HPV vaccine regimen is effective when the ratio of the quantity of CD8+ T cells/Treg cells in the second tissue sample is increased when compared to the ratio of the quantity of CD8+ T cells/Treg in the first tissue sample.

### Claim 5 (depends on 4)

The method of claim 4, wherein at step f1), when the ratio of the quantity of CD8+ T cells/Treg cells in the second tissue sample is the same or decreased when compared to the ratio of the quantity of CD8+ T cells/Treg cells in the first tissue sample, then the HPV vaccine regimen is determined to be ineffective.

### Claim 6

A method for treating a subject having a cervical intraepithelial neoplasia (CIN) comprising: a) obtaining at least one first tissue sample from the CIN of the subject; b) administering to the subject a first vaccine construct comprising HPV16 E7 antigen one or more times; c) administering to the subject a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18; d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c); e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples; and f) determining that the HPV treatment is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.

### Claim 7 (depends on 6)

The method of claim 6, wherein at step d), the at least one or more samples are obtained at 4 weeks to about 8 weeks after step c).

### Claim 8 (depends on 6)

The method of claim 6, further comprising: step e1) measuring the quantity of Treg cells in the intraepithelial tissue of the first and second CIN samples; and f1) determining that the HPV vaccine regimen is effective when the ratio of the quantity of CD8+ T cells/Treg cells in the second tissue sample is increased when compared to the ratio of the quantity of CD8+ T cells/Treg in the first tissue sample.

### Claim 9

A method for determining the effectiveness of an HPV vaccine regimen with an adjuvant on a subject having a cervical intraepithelial neoplasia (CIN) comprising:
a) obtaining at least one first tissue sample from the CIN of the subject;
b) administering to the subject an effective amount of a first vaccine construct comprising HPV16 E7 antigen one or more times;
c) administering to the subject an effective amount of a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18, and an effective amount of an adjuvant;
d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c);
e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples; and
f) determining that the HPV treatment is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.

### Claim 10

A method for treating a subject having a cervical intraepithelial neoplasia (CIN) comprising:
a) obtaining at least one first tissue sample from the CIN of the subject;
b) administering to the subject an effective amount of a first vaccine construct comprising HPV16 E7 antigen one or more times;
c) administering to the subject an effective amount of a second vaccine construct comprising both E6 and E7 antigens from both HPV16 and HPV18, and an effective amount of an adjuvant;
d) obtaining at least one or more second tissue samples from the CIN of the subject about 4 to about 24 weeks after step c);
e) measuring the amount of CD8+ T cell infiltrates in the intraepithelial tissue of the first and second CIN samples; and
f) determining that the HPV treatment is effective when the amount of CD8+ T cell infiltrates in the second tissue sample is increased when compared to the amount of CD8+ T cell infiltrates in the first tissue sample.

### Claim 11 (depends on 9)

The method of claim 9, wherein at step d), the at least one or more samples are obtained at 4 weeks to about 8 weeks after step c).

### Claim 12 (depends on 10)

The method of claim 10, wherein at step d), the at least one or more samples are obtained at 4 weeks to about 8 weeks after step c).

### Claim 13 (depends on 9)

The method of claim 9, wherein at step f), when the quantity of CD8+ T cells in the second tissue sample is the same or decreased when compared to the quantity of CD8+ T cells in the first tissue sample, then the HOV vaccine regimen is determined to be ineffective.

### Claim 14 (depends on 10)

The method of claim 10, wherein at step f), when the quantity of CD8+ T cells in the second tissue sample is the same or decreased when compared to the quantity of CD8+ T cells in the first tissue sample, then the HOV vaccine regimen is determined to be ineffective.

### Claim 15 (depends on 9)

The method of claim 9, further comprising: step e1) measuring the quantity of Treg cells in the intraepithelial tissue of the first and second CIN samples; and f1) determining that the HPV vaccine regimen is effective when the ratio of the quantity of CD8+ T cells/Treg cells in the second tissue sample is increased when compared to the ratio of the quantity of CD8+ T cells/Treg in the first tissue sample.

### Claim 16 (depends on 10)

The method of claim 10, further comprising: step e1) measuring the quantity of Treg cells in the intraepithelial tissue of the first and second CIN samples; and f1) determining that the HPV vaccine regimen is effective when the ratio of the quantity of CD8+ T cells/Treg cells in the second tissue sample is increased when compared to the ratio of the quantity of CD8+ T cells/Treg in the first tissue sample.

### Claim 17 (depends on 15)

The method of claim 15, wherein at step f1), when the ratio of the quantity of CD8+ T cells/Treg cells in the second tissue sample is the same or decreased when compared to the ratio of the quantity of CD8+ T cells/Treg cells in the first tissue sample, then the HPV vaccine regimen is determined to be ineffective.
